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Abstract
Background: During chronic lung infections of cystic fibrosis patients Pseudomonas aeruginosa populations undergo
extensive evolutionary diversification. However, the selective drivers of this evolutionary process are poorly understood.
To test the effects of temperate phages on diversification in P. aeruginosa biofilms we experimentally evolved
populations of P. aeruginosa for approximately 240 generations in artificial sputum medium with or without a
community of three temperate phages.
Results: Analysis of end-point populations using a suite of phenotypic tests revealed extensive phenotypic
diversification within populations, but no significant differences between the populations evolved with or without
phages. The most common phenotypic variant observed was loss of all three types of motility (swimming, swarming
and twitching) and resistance to all three phages. Despite the absence of selective pressure, some members of the
population evolved antibiotic resistance. The frequency of antibiotic resistant isolates varied according to population
and the antibiotic tested. However, resistance to ceftazidime and tazobactam-piperacillin was observed more
frequently than resistance to other antibiotics, and was associated with higher prevelence of isolates exhibiting
a hypermutable phenotype and increased beta-lactamase production.
Conclusions: We observed considerable within-population phenotypic diversity in P. aeruginosa populations evolving
in the artificial sputum medium biofilm model. Replicate populations evolved both in the presence and absence of
phages converged upon similar sets of phenotypes. The evolved phenotypes, including antimicrobial resistance, were
similar to those observed amongst clinical isolates from cystic fibrosis infections.
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Background
Pseudomonas aeruginosa is an important opportunistic
pathogen that can cause chronic lung infections in pa-
tients with cystic fibrosis (CF) [1] or non-CF bronchiec-
tasis [2]. Once established as a chronic infection, a P.
aeruginosa strain can remain in the lungs of a patient
for life, despite frequent use of antibiotic therapy. During
the infection, the pathogen adopts a biofilm lifestyle,
with evidence from explanted lungs suggesting the for-
mation of free aggregates rather than surface-attached
biofilms [3]. Throughout these long time periods, popu-
lations of P. aeruginosa adapt to the CF lung in several
ways, with isolates often exhibiting phenotypes such as
mucoidy, auxotrophy, hypermutability, loss of known
virulence factors, loss of motility, slower growth in rich
media and resistance to antimicrobials [4–7]. In addition
to flagella-mediated swimming motility, P. aeruginosa
exhibits motility on solid or semi-solid surfaces, using
IV pili for twitching motility [8], and both flagella and
type IV pili for swarming motility [9]. In CF, mutations
occur in genes encoding both type IV pili and flagella.
Recently, it has also become evident that P. aeruginosa
populations in the CF lung can diversify both phenotyp-
ically [7, 10–16] and genetically [14, 17]. In particular,
we have shown that populations of the most common
clone of P. aeruginosa infecting CF patients in the UK,
the Liverpool Epidemic Strain (LES) [18, 19], are highly
diverse [11, 12, 20]. However, the factors driving and
maintaining this diversity, also observed in other CF
pathogens [21], are poorly understood.
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It has been shown that sub-inhibitory concentrations
of antibiotics can drive diversification of P. aeruginosa
populations [22], but other possible contributory factors
include host-responses, other members of the complex
microbial community associated with the CF lung [23]
or the biofilm lifestyle itself [24]. Temperate phages are
abundant in the CF lung [25], and we have demon-
strated previously that LES temperate phages can both
mediate and drive adaptive evolution during experimen-
tal evolution in a biofilm model system, by increasing
the supply of mutations in genes involved in type IV
pilin biogenesis and quorum sensing through insertional
inactivation of bacterial genes [26, 27]). The LES phages
have also been implicated in the competitiveness of the
strain in chronic infection models [28, 29].
To test the hypothesis that temperate phages play an im-
portant role in driving phenotypic diversity, here we analysed
a suite of phenotypic traits in populations of P. aeruginosa
that have been experimentally evolved for approximately 240
bacterial generations with or without an assemblage of three
LES temperate phages (LESφ2, φ3 and φ4) in Artificial Spu-
tum Medium (ASM). ASM is an in vitro environment that
recapitulates the physiochemical properties of lung sputum
and in which P. aeruginosa forms free-floating biofilms [30]
and expresses biofilm-associated genes [31].
Results
Phenotypic diversification and loss of wild-type phenotypes
occurred in both treatment and control populations
Twelve replicate populations of P. aeruginosa PAO1 were
experimentally evolved for ~240 generations in ASM in the
absence (#1-6) [control treatment] or presence (#7-12) of
three temperate LES phages. At the end of the evolution ex-
periment, 40 randomly-selected isolates per population were
characterised by assessing a suite of phenotypic traits previ-
ously associated with adaptation to the CF lung [7]. These
were three types of motility (swimming, swarming and
twitching), auxotrophy, hypermutability, and resistance to
each of the three LES phages (LESφ2, φ3 and φ4). These
data are available in Additional File 1. Extensive phenotypic
diversity was observed in all endpoint populations. Analysis
of molecular variance (AMOVA) indicated that the majority
of the phenotypic variance was associated with diversity
within (74%) and between populations (24%), whereas less
than 2% of the variation was explained by treatment (i.e.
presence/absence of phages) (Table 1). From the 480 iso-
lates, 57 different haplotypes were identified, based on
eight phenotypic traits. The haplotype of the ancestor was
very rare in the evolved populations; only 8/480 isolates
shared the ancestral haplotype, all of which were recov-
ered from the control treatment. The most common
haplotype constituted 23% of isolates and was observed in
all but one population. This haplotype was characterised
by loss of all three types of motility and resistance to all
three LES phages, but displayed the wild-type mutation
rate and growth on minimal media phenotypes.
In order to visualise variation between populations, a
principal component analysis (PCA) was applied to the
multivariate phenotypic dataset (Fig. 1). The first princi-
pal component was strongly associated with twitching
motility (Fig. 1a). There was a large degree of overlap be-
tween isolates from the two treatments, suggesting that
populations from the different treatments evolved along
similar trajectories (Fig. 1b). While some degree of
clustering by population was observed, extensive di-
versification within individual populations was evident
(Fig. 1c). Many isolates exhibited loss of multiple phe-
notypes, but there was considerable variation in the
proportion of mutants in each population (Fig. 2).
However, there was no difference between the control
and phage treatments for any of the phenotypes (Wilcoxon
rank-sum test, P > 0.05).
Endpoint isolates were tested for resistance to each of
the LES phages. Phage resistance was widespread in both
treatments (Fig. 3). The majority of isolates were resist-
ant to all three phages in all but one of the populations
that was not exposed to phages (#5), in which 93% of
isolates remained susceptible to all three phages.
Resistance to antibiotics
Disk diffusion assays revealed that all of the isolates tested
(40/40) from every population were as susceptible to a
panel of antibiotics as the ancestor. The method was
therefore adapted to look for resistant isolates that may be
present at a low frequency in the population. Entire popu-
lations were spread on to agar plates containing antibiotics
at clinically relevant resistance breakpoint levels. The fre-
quency of antibiotic resistant isolates varied according to
the population and the antibiotic (Fig. 4). The highest fre-
quency of tazobactam-piperacillin resistance, observed in
the phage-treated population #11 (0.08%), exceeded that
seen with the control mutator strain, PAO1ΔmutS. Resist-
ance to ceftazidime and tazobactam-piperacillin arose
more frequently than resistance to other antibiotics. No
meropenem resistant isolates were identified.
In order to assess the extent to which the mutator
phenotype was linked to the high frequencies of antibiotic
Table 1 Analysis of molecular variance of the phenotypic
diversity of haplotypes identified in endpoint populations
Variance component σ2 Variance % of total variance (100) P




Between treatments 0.015 2 0.26
Variance was partitioned into within and between populations, and between
treatments. Significance was tested by Monte-Carlo permutation tests
(49 permutations)
Davies et al. BMC Microbiology  (2017) 17:3 Page 2 of 10
resistant cells, the frequency of hypermutators in a
population was plotted against the frequency of isolates
resistant to ceftazidime and tazobactam-piperacillin
(Fig. 5). Higher frequencies of hypermutators were linked
to frequencies of resistance against both tazobactam-
piperacillin (Spearman’s rank correlation coefficient: ρ =
0.69, p < 0.05), and ceftazidime (Spearman’s rank correl-
ation coefficient: ρ = 0.72, p < 0.01). To further character-
ise the nature of the spontaneously occurring antibiotic
resistance, Minimum Inhibitory Concentration (MIC)
values were determined for two sets of 20 colonies from
population #11 identified as resistant to either ceftazidime
or tazobactam-piperacillin. The MIC values for ceftazi-
dime (32–128 mg l−1); and tazobactam-pipericillin (128–
256 mg l−1) were at least two-fold higher than the clinical
resistance breakpoints (8 mg l−1 and 16 mg l−1 respectively
[32]). All isolates found to be resistant to one antibiotic
were also resistant to the other. A chromogenic beta-
lactamase detection assay was conducted on five randomly
selected isolates from each antibiotic medium, using
nitrocefin. Beta-lactamase production above the level
of the control (PAO1) was observed in all of the iso-
lates tested (Fig. 6). Antibiotic resistance data and
data for beta-lactamase production are available in
Additional File 2.
Discussion
Consistent with clinical studies reporting extensive
phenotypic diversity in P. aeruginosa populations recov-
ered from the sputa of CF patients [10, 11, 13, 14], popula-
tions of P. aeruginosa grown in ASM exhibited substantial
phenotypic heterogeneity. Notably we observed the evolu-
tion of many phenotypic variants that are also commonly
found amongst isolates from CF patients. As with natur-
ally occurring populations in the CF lung [10, 11], the
majority of the diversity in our evolved populations was
within populations rather than between populations. Al-
though our previous genomic analyses suggested that the
phages play a key role in accelerating the evolution of key
phenotypes [26], our populations treated with or without
phages evolved along similar trajectories, and converged
upon similar suites of evolved phenotypes [26, 33].
Previous studies of CF isolates have reported loss of
swimming, swarming and twitching motility [10]. Al-
though it has been proposed that this loss of motility
may be an immune avoidance strategy [4], the lack of
any immune system in our model suggests that loss of
motility may evolve, at least in part, because of other
Fig. 1 Exploratory principal component analysis of multivariate
phenotype data. (a) Variable factor map, (b) individual factor map,
labelled with experimental treatment and (c) individual factor map,
labelled with population number. The Eigenvalues for the first and
second components were 2.07 and 1.59, respectively
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Fig. 2 Boxplots of the proportion of isolates per population displaying the mutant phenotype for twitching motility (a), swarming motility
(b), swimming motility (c), hypermutability (d) and auxotrophy (e). Thick black horizontal lines represent the median, the box represents the
upper and lower quantiles, and the circles represent outliers. 40 isolates were tested per populations (6 populations per treatment)
Fig. 3 Phage resistance of endpoint isolates to LESφ2-4. Bars are coloured according to the particular phage combination to which resistance
was observed. High titre pure phage stocks were spotted onto a soft-agar lawn of each isolate and scored as resistant if no lysis was observed
after overnight incubation at 37 °C
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selective pressures. These could include the viscosity of
the lung environment, though this remains a hypothesis
yet to be tested. Although a role for type IV pili in bio-
film formation has been suggested [34, 35], a study
examining clinical isolates observed no correlation be-
tween biofilm production and motility [36]. Our obser-
vations suggest that type IV pili are not required for the
formation of the kind of free-floating biofilms that occur
in the ASM model.
A high frequency of hypermutators was observed in
some evolved populations, but there were large differences
between populations, ranging from 0 to > 90% hypermuta-
tors. An elevated mutation rate can be detrimental due to
the increased risk of deleterious mutations, but hypermu-
tability can reach fixation in a population by hitch-hiking
with beneficial mutations [37], and can be advantageous
in a novel environment, accelerating adaptation [38]. The
mutator phenotype has been shown to occur during
Fig. 4 Frequency of bacterial cells in whole populations displaying clinical resistance to a panel of antibiotics (arcsine transformed). Frequencies
were calculated after plating endpoint populations onto antibiotic free media, and media containing antibiotics at the clinical resistance breakpoint
level. Planktonic PAO1 and PAO1 grown in ASM were included as negative controls. PAO1ΔmutS was included as a mutator strain control. Error
bars ±1 S.E.M. Piperacillin/tazobactam (TZP); ceftazidime (CAZ); ciprofloxacin (CIP); tobramycin (TOB); colistin (COL)
Fig. 5 The correlation between the frequency of hypermutators in a population and the frequency of resistant isolates (arcsine transformed). Ceftazidime
(CAZ); piperacillin/tazobactam (TZP); n= 12
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biofilm growth and may confer intrinsic fitness benefits,
such as significantly enhanced microcolony growth [39],
or overproduction of the H2O2-degrading enzyme cata-
lase, leading to increased resistance to oxidative stress
[40]. The hypermutability phentotype has also been linked
with antibiotic resistance [41, 42], and in our study a clear
correlation was observed between the frequency of hyper-
mutators in a population and the frequency of clinically
resistant isolates. Increased basal production of Beta-
lactamase has been observed previously in mutator strains
[43]. The finding that clinically resistant isolates are
present at low frequency in hypermutable populations,
even in the absence of antibiotic selection, suggests that
factors other than antibiotic therapy per se can drive anti-
microbial resistance in chronic lung infections. The role of
mutator phenotypes in driving evolution in P. aeruginosa
surface-attached biofilm systems, including an increase in
the frequency of mutations implicated in antibiotic resist-
ance, has been described previously [39]. Evolution of
antibiotic resistance has also been shown during biofilm
growth for Escherichia coli [44]. Here, we demonstrate the
development of resistance in a free-floating biofilm model
systems designed to mimic sputum.
The diversification observed in ASM over this relatively
short timescale could be driven by growth in a biofilm. It
is known that spatially structured environments, like the
viscous ASM, can select for the evolution of diversity [45].
Previous studies further suggest that P. aeruginosa diversi-
fies when grown as a surface-attached biofilm, and this di-
versity helps protect against oxidative stress [24]. It has
been suggested that this was due to the “insurance effect”,
which posits that biodiversity has a buffering effect over
time on productivity, as well as raising the overall mean
productivity of an ecosystem [46]. However, the applicabil-
ity of the insurance hypothesis to bacterial biofilms has
been questioned [47]. Our observations suggest that diver-
sification of biofilm populations, especially those that have
evolved hypermutability, could potentially increase their
evolutionary responsiveness in the event of antibiotic
treatment by providing standing genetic variation for anti-
biotic resistance upon which natural selection can act.
Conclusions
We have demonstrated that many of the phenotypic ad-
aptations observed amongst P. aeruginosa isolates from
CF chronic infections occur during evolution in a model
designed to mimic the CF sputum environment, even in
the absence of any selection due to host responses or an-
tibiotics. Although we have shown previously that
phages can alter the mode and rate of adaptive evolution
[26], comparable sets of phenotypes eventually occurred
both in the presence and absence of phages. It is, how-
ever, worth noting that similar phenotypes can be driven
by sub-inhibitory concentrations of antibiotics in non-
biofilm systems [48]. In CF, it has been proposed that
the maintenance of phenotypically diverse P. aeruginosa
populations may be a consequence of the spatial hetero-
geneity of the lung, leading to regional isolation of separ-
ately evolving communities [15]. Here we show that
similar population heterogeneity occurs in an artificial
sputum biofilm system, emphasizing the potential utility
of this model as a tool to facilitate a better understand-
ing of the factors driving P. aeruginosa adaptation and
diversification during infections.
Fig. 6 Beta-lactamase production in ceftazidime and tazobactam-piperacillin resistant isolates. Activity was measured using nitrocefin, in a
chromogenic assay by calculating the change in A486/390 per minute. The dashed line indicates the value of the negative control (PAO1).
Ceftazidime (CAZ); piperacillin/tazobactam (TZP). Bars indicate standard error
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Methods
Bacterial strains, bacteriophages and growth conditions
The laboratory reference strain P. aeruginosa PAO1, origin-
ally isolated from a wound in Melbourne, Australia in 1954
[49], was used as a model host because it is known to be fully
susceptible to LES φ2-4. P. aeruginosa LESB58 was isolated
from a CF patient in Liverpool in 1988 [19]. Bacteriophages
were isolated from the P. aeruginosa LESB58 as described
previously [50]. The challenge experiment was performed
using PAO1 cultures grown in ASM [22, 30] at 37 °C,
60 rpm for 96 h periods as described previously [26]. Prior
to the challenge experiment and in follow up experiments,
all bacterial strains and phages were grown and propagated
in standard Luria Bertani broth (LB). Phage suspensions (1
× 108 – 1 × 1011 p.f.u ml−1) were stored in LB at 4 °C.
Challenge experiment
Twelve replicate ASM cultures (hereafter referred to as
populations) were initiated by inoculation of approxi-
mately 5 × 107 cells of mid-exponential phase PAO1 into
5 ml ASM, followed by 24 h incubation (37 °C, 60 rpm).
Equal numbers of each LES phage (LES φ2 – 4) were then
added, once only, to 6 replicates (populations 7–12), to a
total multiplicity of infection (MOI) of 0.1. The remaining
six replicates were designated phage-free controls (popula-
tions 1–6). Each population was incubated for a further
72 h before degradation of biofilm structures using
Sputasol (Oxoid) as described previously [30]. The biofilm
homogenate was transferred (1:100) into fresh ASM (12 ×
5 ml) and incubated for a further 96 h. This process was
repeated every 96 h for 120 days (30 transfers and ap-
proximately 240 bacterial generations).
Phenotypic diversity of endpoint populations
At the end of the challenge experiment, 40 evolved isolates
were obtained from each population by plating onto
Columbia media and patching of randomly selected colonies
onto fresh Columbia media. All isolates were stored in LB
with 30% (v/v) glycerol at −80 °C. A total of 240 isolates for
each treatment were subjected to a series of phenotypic tests.
For growth rate in LB, overnight cultures were diluted
1:100 and 200 μl added to wells (n = 4 per isolate) of a
clear-bottomed 96 well plate. The plate was held at 37 °C,
with shaking at 100 r.p.m. in an Omega fluostar plate
reader. The OD600 was measured every 5 min and the
doubling time in the exponential phase of growth calcu-
lated for each well. Two biological replicates were per-
formed per isolate. Ten isolates were tested per population.
For auxotrophy, a single colony was patched onto M9
minimal media and incubated at 37 °C. Isolates display-
ing no growth after 18 h were classed as auxotrophic.
For hypermutability, 10-fold serially diluted overnight
cultures grown in LB were spotted onto LB agar plates
containing 300 μg ml−1 rifampicin. Plates were incubated
overnight at 37 °C. As described previously [12], isolates
were classed as hypermutable if growth on rifampicin
was comparable to PAOΔmutS (ie. different by less than
10-fold), a known hypermutator.
For swarming motility, a small portion of a colony was
lightly touched on to the surface of media containing 0.5%
(w/v) bacteriological agar as described previously [51].
Plates were incubated for 16 h at 37 °C and the diameter
of the swarm was measured at the widest point, using a
strain PAO1 pilA mutant as a negative control. An isolate
with a diameter <6 mm was considered swarming defi-
cient. For swimming motility, a small portion of a colony
was lightly touched to the surface of a swimming plate
[52]. Plates were wrapped loosely in clingfilm to prevent
dehydration, and incubated without inversion for 14 h.
The visible diameter of bacterial growth was measured at
the widest point. Using the non-motile P. aeruginosa
LESB58 was used as a negative control, an isolate with a
diameter <20 mm was considered swimming deficient.
Twitching motility was measured in duplicate as described
previously [53], using ancestral PAO1 as a positive control.
Isolates with a zone diameter <10 mm were considered to
have impaired twitching motility.
To test bacterial resistance to the phages used in this
study (LESφ2, φ3 and φ4), a modified version of the phage
spot assay was used. 20 μl of 10-fold diluted overnight cul-
ture was mixed with 200 μl agar overlay and poured into a
well containing 1 ml bottom agar, in a 25 well square petri
dish (Fisher Scientific). High titre (>1x1010 pf.u. ml-1)
preparations of each phage were spotted on top. Isolates
were classed as resistant to a phage if there was no evi-
dence of bacterial lysis after overnight incubation at 37 °C.
Antibiotic susceptibilities
Susceptibilities to six antibiotics were determined using
the disc diffusion method, as described previously [11].
The antibiotics were: piperacillin/tazobactam, ceftazidime,
meropenem, ciprofloxacin, tobramycin and colistin. To
detect resistant isolates at a low abundance in a popula-
tion, a modified version of the agar dilution method was
developed. Whole population cultures were adjusted to
the turbidity equivalence of a McFarland standard 0.5
(Beckton Dickinson), and 100 μl was plated directly onto
Mueller-Hinton Agar plates containing antibiotics at the
breakpoint levels for clinical resistance [32]. After over-
night growth at 37 °C, colonies growing on antibiotic-
containing media were calculated as a proportion of total
population counts. “Planktonic” PAO1 grown in LB and
PAO1 grown in ASM were included as controls.
Beta-lactamase assay of beta-lactam resistant isolates
Isolates were passaged twice through antibiotic-free
media (LB agar) to ensure basal (as opposed to induced)
beta-lactamase levels were being studied. Cultures were
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grown in LB to an Absorbance at 600 nm of 0.3, and
nitrocefin (Merck-Millipore) was added to a final con-
centration of 51.6 μg ml−1. As the λmax of nitrocefin
changes from 390 nm (in the absence of beta-lactamase)
to 486 nm upon hydrolysis, the absorbance at both
wavelengths was measured every 5 min, for 35 min. The
A486 nm/390 nm ratio was calculated for every time
point as an indicator of beta-lactamase production. Five
biological replicates were performed for each isolate.
Analysis of molecular variance (AMOVA)
At the end of the challenge experiment, 40 evolved isolates
were selected at random from each population and
screened for eight phenotypic traits (the three types of mo-
tility, auxotrophy, hypermutability, resistance to each of
the three phages). Isolates were classified as different hap-
lotypes based on the combination of phenotypic traits
displayed. For each trait, isolates were scored a 0 if they
displayed the same phenotype as the ancestor, or a 1 if
they displayed a mutant phenotype. Here we define a
haplotype as a unique combination of phenotypic traits.
The evolutionary distance between the haplotypes was
estimated by creation of a Euclidean distance matrix.
AMOVA was performed using the ade4 package in R [54];
the distance matrix was partitioned into sub-matrices for
the various subdivisions of the data, including treatment
(control or phage-treated), population and individual iso-
lates. The sums of squares were computed and analysed in
a nested ANOVA framework and significance tested by
Monte-Carlo permutation tests (49 permutations). Such
an approach has been used previously to assess diversity of
clinical P. aeruginosa isolates, using phenotype data [11].
Principal component analysis (PCA)
Phenotypic data from the host-phage coevolution experi-
ment resulted in large, multivariate datasets. To explore
the underlying structure of the data and elucidate the fac-
tors that are responsible for much of the variance, PCA
was used as an exploratory data analysis tool, using the
ade4 package [54] in R. Complete datasets (i.e. data for all
40 isolates within each population) were available for all
but two of the variables (biofilm formation and doubling
time in LB). For the incomplete variables, only the first 10
isolates of every population were tested, due to the large
amount of time and work required to test these specific
phenotypes. PCA in R cannot proceed with missing
values, but numerous methods exist to allow missing
values to be ignored or replaced. Multiple imputation was
chosen as a method to replace the missing data, using the
mi package [55] in R, as it enables existing data to be
retained. Data were plotted with dudi PCA scatter plots,
and the independent variables (phage-treatment and
population) overlaid, using the s.class function. Data for
seven phenotypes were included in the PCA analysis:
swimming, swarming and twitching motility, hypermuta-
bility, growth rate, biofilm formation and auxotrophy.
Additional files
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production. (XLSX 18 kb)
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